Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

Dialysis patients with kidney failure more likely to develop serious complications from flu

For most people, the flu is a temporary setback that makes them feel under the weather for a week or two. For dialysis patients with kidney failure, however, the flu is a serious health threat that can lead to pneumonia and other life-threatening complications.

1 Oct 2011

Patients with chronic kidney disease do not need to undergo painful invasive procedures

Equations that estimate a patient's kidney function work as well as direct, invasive measurements, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

16 Sep 2011

Demand for kidney transplant and dialysis increases due to diabetes prevalence

A survey reveals that the need for kidney transplants and dialysis is expected to soar by 2020 mainly due to a rise in diabetics developing chronic kidney disease and needing treatment. The total number of Australians being treated for end-stage kidney disease is forecast to rise by up to 80 per cent to about 4300 in the coming decade. While the fact that Australia's population is ageing and growing means more people are likely to develop end-stage kidney disease, the number of diabetics with the condition is also on the rise.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Blood levels of FGF-23 can help predict CKD patients at risk of heart problems

The blood levels of a particular hormone can help predict which kidney disease patients will develop heart problems, need dialysis, and die prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

9 Sep 2011

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has amended its agreement with Shiva Biomedical, LLC.

6 Sep 2011

DaVita completes acquisition of DSI

DaVita Inc., a leading provider of kidney care services committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), announced today that it has closed its acquisition of DSI Renal, Inc.

6 Sep 2011

High blood phosphate levels can set CKD patients on a rapid path to kidney failure

High blood phosphate levels can set chronic kidney disease (CKD) patients on a rapid path to kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

19 Aug 2011

New tool can identify patients at high risk of venous thromboembolism

A new risk prediction tool can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might need preventative treatment, says a study published on bmj.com today.

17 Aug 2011

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.

12 Aug 2011

PUFA intake linked to reduced risk of heart failure, kidney disease and preterm delivery

Omega-3 polyunsaturated fats (PUFAs) found in seafood may reduce arterial stiffness and improve heart function in chronic heart failure, according to new research. These fats, better known as EPA and DHA, may also help in the immediate aftermath of a stroke.

11 Aug 2011

Study sheds new light on how surgery impacts chronic kidney disease, bone health

Researchers at the University of California, San Diego School of Medicine have shed new light on how surgery impacts both chronic kidney disease and bone health, particularly in women.

5 Aug 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

Routine dipstick urine test may identify individuals with silent kidney disease

A simple and inexpensive urine test routinely done in family doctors' offices may be the key to identifying individuals who are silently undergoing rapid kidney function decline, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

29 Jul 2011

Reprogrammed kidney cells could make transplants and dialysis things of the past

Approximately 60 million people across the globe have chronic kidney disease (CKD), and many will need dialysis or a transplant. Breakthrough research published in the Journal of the American Society Nephrology indicates that patients' own kidney cells can be gathered and reprogrammed.

28 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Dialysis patients with kidney failure more likely to develop serious complications from flu

Patients with chronic kidney disease do not need to undergo painful invasive procedures

Demand for kidney transplant and dialysis increases due to diabetes prevalence

KAI enters KAI-4169 development and commercialization agreement with Ono

Blood levels of FGF-23 can help predict CKD patients at risk of heart problems

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

DaVita completes acquisition of DSI

High blood phosphate levels can set CKD patients on a rapid path to kidney failure

New tool can identify patients at high risk of venous thromboembolism

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

PUFA intake linked to reduced risk of heart failure, kidney disease and preterm delivery

Study sheds new light on how surgery impacts chronic kidney disease, bone health

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Routine dipstick urine test may identify individuals with silent kidney disease

Reprogrammed kidney cells could make transplants and dialysis things of the past

FDA accepts peginesatide NDA for anemia associated with CKD

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in